Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octreotide LAR
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Peptides
- Administration
- Intramuscular
01
Overview
Octreotide LAR is a synthetic, eight-amino-acid analogue of the natural hormone somatostatin, designed for prolonged release. It functions by acting as a somatostatin analogue, which limits beta-cell insulin secretion by inhibiting the G0 protein associated with the widening of the voltage-gated calcium channel. Additionally, it inhibits the secretion of gastric acid, pancreatic enzymes, and bile, prolongs intestinal transit time, and decreases gallbladder contractility. Octreotide LAR also suppresses the release of various pituitary and gastroenteropancreatic hormones, including growth hormone (GH), thyroid stimulating hormone (TSH), glucagon, cholecystokinin (CCK), vasoactive intestinal peptide (VIP), gastrin, and ghrelin. It is developed by companies such as Novartis Pharmaceuticals and is used in conditions like advanced gastroenteropancreatic neuroendocrine tumors, acromegaly, polycystic ovary syndrome, and obesity with insulin hypersecretion.
- Brand names
- Sandostatin LAR Depot
- Other names
- Octreotide Long Acting Release
02
Targets
SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on octreotide LAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octreotide LAR.